NCT04816838View on ClinicalTrials.gov

A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations

NARecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 10, 2021

Primary Completion Date

July 31, 2025

Study Completion Date

October 31, 2025

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Osimertinib

"\* Osimertinib 80mg once a day(QD) oral(PO)~Neoadjuvant Period -If there is no disease progression or unacceptable toxicity, treatment is performed for 2cycles at 1 cycle (28 days) interval~Adjuvant Period~\- If there is no disease progression of unacceptable toxicity, treatment fis performed for 3years at intervals of 1cycle(28days)"

Trial Locations (1)

Unknown

RECRUITING

Yonsei University Health System, Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER